Rhythm Pharmaceuticals, Inc. (RYTM) Raw materials — Quarterly & Annual

Screener

Raw materials at other companies

Eli LillyLLY

$4.13B+31.0%

Mirum Pharmaceuticals, Inc.MIRM

$2.61M-10.6%

Neurocrine BiosciencesNBIX

$30.7M-3.8%

BridgeBio PharmaBBIO

$27.85M—

Zevra Therapeutics, Inc.ZVRA

$15K-28.6%

Rigel PharmaceuticalsRIGL

$3.43M—

Other financials

Income statement

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

Market cap$7.96B+27.1%

Enterprise value$8.01B+28.3%

P/S36.7×-3.4×

Profitability

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterialsAndSupplies.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed: May 5, 2026, 4:15 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001628280-26-030549

Line item	March 31,2026	December 31,2025
Raw Materials	$5,653	$6,745
WIP	1,781	1,631
Finished Goods	21,217	17,377
Total Inventory	$28,651	$25,753

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s raw materials?: Rhythm Pharmaceuticals, Inc. (RYTM) reported raw materials of $5.65M in Q1 2026.
What does raw materials mean?: Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk